Daniel W. Chan

Daniel W. Chan

Talk Title: Clinical Proteomics: My adventures in wonderland.


Professor Daniel W Chan is Professor of Pathology, Oncology, Radiology, Urology and the Director, Center for Biomarker Discovery and Translation ( at the Johns Hopkins University and the Director of Clinical Chemistry Division and Co-Director of Pathology Core Laboratories at the Johns Hopkins Hospital. He developed an ovarian cancer diagnostic test OVA1 (5 proteomic biomarkers discovered using mass spectrometry). In 2009, OVA1 became the 1st FDA cleared proteomic IVDMIA and Overa (2nd generation OVA1) was cleared by the FDA (2016). Dr. Chan is the PI of the NCI EDRN Biomarker Reference Laboratory and the Clinical Proteomics Tumor Analysis Consortium (CPTAC). He was a founder and a member of the USHUPO Board of Directors. He is the Editor-in-Chief of Clinical Proteomics and published 5 books, 40 book chapters and >300 scientific articles. Dr. Chan received >20 awards from many scientific organizations including the Inaugural HUPO Translational Proteomics Award (2014).

ABSTRACT: Clinical Proteomics: My adventures in wonderland.
Professor Daniel W Chan, The Johns Hopkins University

During the last decade of proteomic research, significant progress has been made in the advancement of new technologies and the discovery of potential biomarkers. However, limited successes have been shown in the translation of proteomic discoveries into clinical practice. Clinically, one of the major goal of cancer biomarker discovery is to detect early stage lethal cancer. In my presentation, I will take you with me through the journey of my personal adventures in the wonderland of clinical proteomics. I will discuss our strategies and give specific examples for biomarker discovery, validation to translation and our research partnerships with industry, the National Cancer Institute (NCI) Early Detection Research Network (EDRN) and the Clinical Proteomics Tumor Analysis Consortium (CPTAC) in linking genomics with proteomics. The successful translation of clinical proteomics into clinical practice will require close collaboration between researcher, industry, regulator and clinician/clinical laboratory.